SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
MedTech Acquisition Corporation (MTAC) .
本页证实的标准:
- VALUE (0/100, 未通过) — 综合估值评分低于60/100的通过门槛。
SharesGrow 综合评分： 32/100 其中 0/7 项标准通过。
SharesGrow 7-Criteria Score
~
健康
50/100
Debt-to-Equity & liquidity
→ Health
估值概览 — MTAC
估值倍数
P/E (TTM)0.0
前瞻 P/EN/A
PEG 比率N/A
前瞻 PEGN/A
P/B 比率0.00
P/S 比率9.52
EV/EBITDA0.0
每股数据
EPS (TTM)$-1.84
每股账面价值$0.00
每股营收$1.19
每股自由现金流$0.00
收益率与内在价值
盈利收益率N/A
股息收益率0.00%
P/E Ratio & Earnings Yield
每股收益 (EPS) 历史
| Year |
EPS（稀释） |
营收 |
净利润 |
净利润率 |
| 2020 |
$-1.04 |
$5.43M |
$-31.83M |
-585.8% |
| 2021 |
$-0.92 |
$8.4M |
$-28.85M |
-343.4% |
| 2022 |
$-1.59 |
$12.4M |
$-47.19M |
-380.6% |
| 2023 |
$-2.23 |
$18.51M |
$-59.04M |
-318.9% |
| 2024 |
$-1.25 |
$29.43M |
$-33.23M |
-112.9% |
| 2025 |
$-1.84 |
$45.15M |
$-69.69M |
-154.3% |
